Skip to main content
. 2016 Jan 9;7(7):7856–7865. doi: 10.18632/oncotarget.6856

Figure 3. GPR171 triggers proliferation of lung cancer cells in vivo.

Figure 3

A. Cell viability assays of Calu-6 cells treated with anti-GPR171 antibody (ab60843; Abcam), IgG control antibody, or vehicle (PBS) control. Results are presented as means ± SEM (error bars) (n = 3; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control IgG, Student's t test). B. Effects of anti-GPR171 antibody on the growth of Calu-6 xenograft tumors. Data are presented as mean tumor volume ± SEM (error bars) (n = 5; *P < 0.05, **P < 0.01 vs. control IgG, Student's t test). C. BALB/c nude mice bearing Calu-6 xenograft tumors treated with control or anti-GPR171 antibodies.